Literature DB >> 9599352

Quality of life of patients with prostate cancer treated with surgery or radiation therapy.

C H Yarbro1, C E Ferrans.   

Abstract

PURPOSE/
OBJECTIVES: To compare the quality-of-life (QOL) perceptions of men treated for prostate cancer with surgery to those of men treated for prostate cancer with radiation therapy.
DESIGN: A two-group descriptive study.
SETTING: Midwestern community cancer center and teaching hospital. SAMPLE: The study group consisted of 121 men: 68 treated by radical prostatectomy and 53 treated with radiation therapy.
METHODS: Mailed survey using the Quality of Life Index (QLI) Cancer Version and the University of California at Los Angeles Prostate Cancer Index. MAIN RESEARCH VARIABLES: QOL; level of urinary, bowel, and sexual function; impact of dysfunction on patients' lives.
FINDINGS: No significant differences were found between the groups in QLI scores, but significant differences were found in urinary, bowel, and sexual function. Urinary function was superior in the radiation therapy group (p = 0.0002). Patients who had undergone surgery were more likely to leak urine every day (p < 0.001). Only 6% of patients who had undergone radiation therapy needed to use pads or diapers as compared to 32% of patients who had undergone surgery. Bowel function was better in the surgery group (p = 0.05). Both groups reported poor sexual function, although it was worse in the surgery group (p = 0.009).
CONCLUSIONS: The patients who were treated with surgery had significantly worse urinary and sexual function and better bowel function than those treated with radiation therapy. QOL scores were consistent with these findings, although they did not differ significantly between groups. IMPLICATIONS FOR NURSING PRACTICE: This information on the problems of survivors of prostate cancer after surgery and radiation therapy and the effects of therapy on QOL will assist nurses in providing patient education, emotional support, and rehabilitative interventions.

Entities:  

Mesh:

Year:  1998        PMID: 9599352

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  8 in total

Review 1.  [Quality of life after radical urologic pelvic surgery and impact of inpatient rehabilitation].

Authors:  O Dombo; U Otto
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

Review 2.  A review of quality-of-life evaluations in prostate cancer.

Authors:  S D Sommers; S D Ramsey
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

3.  Opioid-taking self-efficacy affects the quality of life of Taiwanese patients with cancer pain.

Authors:  Shu-Yuan Liang; She-Anne Ding; Wei-Wen Wu; Chieh-Yu Liu; Chia-Chin Lin
Journal:  Support Care Cancer       Date:  2014-12-30       Impact factor: 3.603

Review 4.  Prostate cancer and health-related quality of life: a review of the literature.

Authors:  David T Eton; Stephen J Lepore
Journal:  Psychooncology       Date:  2002 Jul-Aug       Impact factor: 3.894

5.  The significance of importance: an evaluation of Ferrans and Powers' Quality of Life Index.

Authors:  Peter Hagell; Albert Westergren
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 3.440

6.  The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis.

Authors:  Ahmed Abdelhafez; Khaled Hosny; Ahmed R El-Nahas; Matthew Liew
Journal:  Arab J Urol       Date:  2022-02-27

7.  Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners.

Authors:  Jeffrey A Albaugh; Nat Sufrin; Brittany R Lapin; Jacqueline Petkewicz; Sandi Tenfelde
Journal:  BMC Urol       Date:  2017-06-15       Impact factor: 2.264

8.  SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Authors:  Monika Rucinska; Anna Kieszkowska-Grudny; Sergiusz Nawrocki
Journal:  Strahlenther Onkol       Date:  2016-05-25       Impact factor: 3.621

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.